AKT1 and chronic kidney disease: In addition, proteolysis by caspase-3 is an additional mechanism contributing to muscle atrophy in CKD, and miR-23a/27a can downregulate AKT to reduce caspase-3 activity, resulting in muscle atrophy alleviation [35].